Table 2.
GO and KEGG pathway enrichment analysis of DEGs in HepG2 cells treated with emodin. (Top 5) P<0.05 was considered statistically significant.
| Category | Term | Count | P-Value |
|---|---|---|---|
| Upregulated | |||
| GOTERM_BP | GO:0070370~cellular heat acclimation | 3 | 3.01E-04 |
| GO:0043065~positive regulation of apoptotic process | 10 | 3.04E-04 | |
| GO:0032496~response to lipopolysaccharide | 7 | 0.0011565 | |
| GO:0090084~negative regulation of inclusion body assembly | 3 | 0.0021952 | |
| GO:2001240~negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 4 | 0.0023164 | |
| GOTERM_CC | GO:0005576~extracellular region | 23 | 0.0032977 |
| GO:0030016~myofibril | 3 | 0.0179025 | |
| GO:0005615~extracellular space | 18 | 0.0200543 | |
| GOTERM_MF | GO:0042623~ATPase activity, coupled | 3 | 0.0031569 |
| GO:0004252~serine-type endopeptidase activity | 7 | 0.0097873 | |
| GO:0008236~serine-type peptidase activity | 4 | 0.0102052 | |
| GO:0004947~bradykinin receptor activity | 2 | 0.0141671 | |
| GO:0019904~protein domain specific binding | 6 | 0.0164848 | |
| KEGG_PATHWAY | hsa04010:MAPK signaling pathway | 10 | 2.68E-04 |
| hsa05323:Rheumatoid arthritis | 5 | 0.0066631 | |
| hsa04915:Estrogen signaling pathway | 5 | 0.0100336 | |
| hsa05134:Legionellosis | 4 | 0.010905 | |
| hsa00980:Metabolism of xenobiotics by cytochrome P450 | 4 | 0.0252724 | |
| Downregulated | |||
| GOTERM_BP | GO:0010951~negative regulation of endopeptidase activity | 23 | 3.10E-10 |
| GO:0030198~extracellular matrix organization | 25 | 1.58E-07 | |
| GO:0007156~homophilic cell adhesion via plasma membrane adhesion molecules | 21 | 9.99E-07 | |
| GO:0042060~wound healing | 14 | 5.01E-06 | |
| GO:0042730~fibrinolysis | 8 | 5.57E-06 | |
| GOTERM_CC | GO:0005615~extracellular space | 114 | 8.37E-18 |
| GO:0005576~extracellular region | 124 | 5.51E-16 | |
| GO:0005578~proteinaceous extracellular matrix | 35 | 1.88E-10 | |
| GO:0016021~integral component of membrane | 261 | 2.10E-10 | |
| GO:0005887~integral component of plasma membrane | 96 | 2.35E-09 | |
| GOTERM_MF | GO:0005509~calcium ion binding | 63 | 8.97E-11 |
| GO:0004867~serine-type endopeptidase inhibitor activity | 20 | 1.22E-09 | |
| GO:0005201~extracellular matrix structural constituent | 12 | 2.27E-05 | |
| GO:0005198~structural molecule activity | 23 | 7.88E-05 | |
| GO:0001530~lipopolysaccharide binding | 7 | 9.18E-05 | |
| KEGG_PATHWAY | hsa04610:Complement and coagulation cascades | 18 | 2.02E-10 |
| hsa05146:Amoebiasis | 16 | 5.35E-06 | |
| hsa04512:ECM-receptor interaction | 13 | 6.15E-05 | |
| hsa04974:Protein digestion and absorption | 13 | 6.90E-05 | |
| hsa04611:Platelet activation | 14 | 8.04E-04 |